Business
CareDx to Host Symposium at CEoT Featuring the Latest Multimodality Innovations in Kidney and Lung Transplant Surveillance
Symposium, “Improved Precision with a Multimodality Approach,” Reviews Innovative Solutions for a More Holistic View of Allograft Health SOUTH SAN FRANCISCO,
About this update from Caredx, Inc.
[{"type":"text","content":"Symposium, “Improved Precision with a Multimodality Approach,” Reviews Innovative Solutions for a More Holistic View of Allograft Health\nSOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will host the symposium, “Improved Precision with a Multimodality Approach,” during the annual American Society of Transplantation Cutting Edge of Transplantation (CEoT) virtual meeting taking place April 6-8. The CareDx sponsored lunch symposium will take place on Thursday, April 7. The latest advancements in multimodality surveillance using CareDx’s AlloSure® donor-derived cell-free DNA (dd-cfDNA), AlloMap® gene-expression profiling, and other new emerging modalities for assessing allograft injury, rejection, and infection in kidney and lung transplantation will be presented. Additionally, in an accepted abstract, “Kinetics of dd-cfDNA in Kidney Transplant Recipients Following SARS-CoV-2 Vaccination Booster Administration,” NYU Langone Health highlights the use of AlloSure Kidney for monitoring vaccine-related immunological graft injury. The study showed that the stability of dd-cfDNA after SARS-CoV-2 vaccine booster administration reinforces the vaccine’s safety profile in kidney transplant patients. “CareDx is deeply committed to delivering innovative transplant solutions, and we are excited to share how our best-in-class technologies support and stratify early signs of rejection, help in clinical decision-making, and impact outcomes,” said Reg Seeto, CEO and President of CareDx. “This real-world data clearly demonstrates the power of our non-invasive multimodality solutions in helping to build the molecular patient profile integrated with predictive algorithms that will support timely interventions.” Topics and speakers include: The Predictive Power of AlloSure Kidney: Findings from the ADMIRAL Study,1 presented by Amishi Desai, DO, Associate Professor, Medical Director of Kidney and Pancreas Transplantation and Division Chief of Transplant Nephrology, Loyola University.Introduction to Multimodality Kidney Surveillance, presented by Abdolreza Haririan, MD, MPH, Medical Director of Kidney and P...